Application of 1,2-dihydroxyethyl 2-acetoxybenzoate in the preparation of liver protection drugs
By using 1,2-dihydroxyethyl 2-acetoxybenzoate (Gankang) to reduce cholesterol and triglyceride levels in serum and liver, reducing the burden on the liver, solving the adverse reactions and treatment problems of existing drugs. Effective treatment of hyperlipidemia and liver fibrosis has been achieved.
Patent Information
- Application Number
- CN202410041752.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-01-10
AI Technical Summary
There are adverse reactions to existing drugs for treating hyperlipidemia and liver fibrosis, and there is a lack of effective long-term treatment options, making it difficult to regulate blood lipids and prevent liver fibrosis at the same time.
1,2-dihydroxyethyl 2-acetoxybenzoate (Gankang) is used as a drug, which significantly reduces serum total cholesterol, triglycerides and low-density lipoprotein levels, reduces the burden on the liver, and weakens liver fibrosis , as a safe and effective liver protection drug.
Gankang significantly reduces the indicators of hyperlipidemia and liver fibrosis, and has the characteristics of high safety, convenient medication and low price. It is a safe and effective drug to prevent and treat hyperlipidemia and liver fibrosis.
Smart Images

Figure CN117883457B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to new lipid-lowering and anti-liver fibrosis drugs, in particular to the application of 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester in the preparation of lipid-lowering drugs. Background Art
[0002] Hyperlipidemia refers to high blood lipid levels, such as the increase of total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL-C) in serum, which can directly cause some diseases that seriously endanger human health, such as atherosclerosis and coronary heart disease. Hyperlipidemia can also lead to fatty liver, cirrhosis, cholelithiasis, pancreatitis, hyperuricemia and other diseases. Liver fibrosis is a pathological process in the human body, which appears in the early stage of cirrhosis. It generally refers to the pathological process of abnormal proliferation of connective tissue in the liver, leading to excessive deposition of diffuse cells in the liver. Usually, normal livers can cause hyperlipidemia due to drinking, high-fat, high-sugar and high-salt diets, viral infections, autoimmunity, genetics and metabolism, and drugs, leading to acute hepatitis, further developing into chronic hepatitis and liver fibrosis, and eventually developing into cirrhosis, causing ascites, hepatic encephalopathy and other complications. Clinical studies have shown that most people with sudden cardiac death have abnormal lipids that cause coronary artery sclerosis, and abnormal lipids that cause coronary artery sclerosis may play an important role in ischemic cardiovascular and cerebrovascular events. On the one hand, lipid metabolism disorders aggravate glucose metabolism disorders, and on the other hand, significantly increase the incidence and mortality of diabetic macrovascular complications.
[0003] Most of the commonly used lipid-regulating drugs in clinical practice are chemical synthetic preparations that need to be taken for a long time. Various statins, such as simvastatin and lovastatin, can treat hyperlipidemia and prevent cardiovascular and cerebrovascular accidents. However, long-term or high-dose use of statins may cause serious adverse reactions such as biochemical changes in liver tissue cells or cardiac rhabdomyolysis, which limits its long-term use. The main treatment for liver fibrosis in clinical practice can only be to reduce the burden on the liver and take some liver-protecting drugs and Chinese herbal medicines. At present, there is no specific drug for the treatment of liver fibrosis in clinical practice. Commonly used liver-protecting drugs include magnesium isoglycyrrhizinate, silymarin, obeticholic acid, etc. Chinese herbal medicines mainly include Anluo Huaxian Pills, Compound Biejia Soft Liver Tablets, etc. However, there are still many adverse reactions to liver-protecting drugs and Chinese herbal medicines. Common adverse reactions mainly include abdominal pain, diarrhea, nausea, cough, etc. The pathological process of long-term hyperlipidemia and the specific treatment of induced hepatitis and liver fibrosis are still hot spots and difficult problems in research and development.
[0004] Therefore, it is of great significance to research and develop safe and effective new liver protection drugs, especially blood lipid regulating drugs and anti-liver fibrosis drugs. Summary of the invention
[0005] In view of the defects of the prior art, the purpose of the present invention is to provide a drug with significant liver protection effect, good safety and simple and convenient use.
[0006] In order to achieve the above objectives, the present invention provides the use of 1,2-dihydroxyethyl 2-acetoxybenzoate in the preparation of liver protection drugs.
[0007] The molecular formula of the 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester is C 13 H 16 O5, molecular weight is 252, chemical structure is as follows:
[0008]
[0009] The 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester is a derivative of aspirin, which is prepared by modifying aspirin. Its preparation method and identification refer to Chinese patent application CN110668947A. In this article, the 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester is also referred to as "Gankang".
[0010] Preferably, the liver protecting drug is a lipid-lowering drug.
[0011] More preferably, the lipid-lowering drug reduces total cholesterol, triglycerides and low-density lipoprotein in the serum of hyperlipidemic animals, and reduces the levels of total cholesterol and triglycerides in the liver and the diameter of the liver.
[0012] Preferably, the liver protection drug is an anti-liver fibrosis drug.
[0013] More preferably, the anti-liver fibrosis drug attenuates liver fibrosis, reduces liver weight to body weight ratio, and ALT and AST levels in serum and liver tissue homogenate.
[0014] Preferably, the liver protection drug is a capsule, tablet, powder, granule, sustained-release agent, injection or any other pharmaceutically acceptable preparation.
[0015] Compared with the prior art, the present invention has the following beneficial technical effects: (1) significant effect on lowering blood lipids: 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester can significantly regulate blood lipids. Compared with the most commonly used clinical atorvastatin at the maximum clinical dose, it can significantly reduce serum TC, TG and LDL-C, and can be used as a safe and effective drug for preventing and treating hyperlipidemia; (2) significant effect on anti-liver fibrosis: 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester can significantly improve the liver fibrosis area of mice, and can be used as a safe and effective drug for preventing and treating liver fibrosis; (3) good safety, no obvious toxic side effects; (4) simple and convenient medication, easy to absorb; (5) the drug raw material of the present invention is aspirin, the finished product has strong drugability, low price and high cost performance; (6) easy to transport and store. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The effect of Gankang on the levels of TC (A), TG (B) and LDL-C (C) in the blood, the levels of TC (D) and TG (E) in the liver, and the diameter of the liver (F, G) in golden hamsters with hyperlipidemia.
[0017] Figure 2 The effect of Gankang on the levels of blood lipids TC (A), TG (B) and LDL-C (C), the levels of TC (D) and TG (E) in the liver, and the liver diameter (F, G) in C57BL / 6 mice with hyperlipidemia.
[0018] Figure 3 The effect of Gankang on TC (A) and TG (B) levels in oleic acid-induced hyperlipidemia HepG2 cells.
[0019] Figure 4 This is a schematic diagram of the animal experiment process of Gankang's anti-liver fibrosis.
[0020] Figure 5 Effect of Weigankang on liver morphology in mice with liver fibrosis.
[0021] Figure 6 Effect of Gankang on the ratio of liver weight to body weight in mice with liver fibrosis.
[0022] Figure 7 The effect of Gankang on the liver injury markers alanine aminotransferase ALT (A) and aspartate aminotransferase AST (B) in the serum of mice with liver fibrosis.
[0023] Figure 8 The effect of Gankang on liver injury markers ALT (A) and AST (B) in liver tissue of mice with liver fibrosis.
[0024] Fig. 9 The effect of Gankang on the expression of α-SMA protein in mice with liver fibrosis. DETAILED DESCRIPTION
[0025] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0026] Unless otherwise specified, the experimental reagents or operating techniques used in the examples of the present invention are conventional experimental reagents or operating techniques known and available in the art. For the purpose of brevity, they are not described one by one, but do not affect the implementation of the technical solution. Each experimental data is expressed as mean ± standard deviation.
[0027] Example 1: Experimental study on the efficacy of Gankang on golden hamster animal model
[0028] 1. Experimental Materials
[0029] Experimental animals: 42 SPF male golden hamsters (Mesocricetus auratus) weighing 110-130 g
[0030] Test drug: 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester (Gankang)
[0031] Maintenance feed: purchased from Keao Xieli (Tianjin) Feed Co., Ltd.
[0032] High-fat feed: purchased from Beijing Huafukang Biotechnology Co., Ltd., the feed formula contains 20.0% sucrose, 15% lard, 1.2% cholesterol, 0.2% sodium cholate, appropriate amount of casein, calcium hydrogen phosphate, stone powder, etc. In addition to crude fat, the moisture, crude protein, crude fat, crude fiber, crude ash, calcium, and phosphorus of the high-fat feed must meet the national standards for maintaining feed. The feed is clean grade, vacuum packed, and stored at 4°C. The above percentages (%) are all weight percentages.
[0033] 2. Experimental Principle
[0034] Feeding animals with the above-mentioned high-fat feed containing cholesterol, sucrose, lard, and sodium cholate can form an animal model of lipid metabolism disorder. Then, administering drugs to the animals can detect the effects of the test drugs on hyperlipidemia, and determine the effects of the test drugs on the animals' lipid absorption, lipoprotein formation, and lipid degradation or excretion.
[0035] Determination of hyperlipidemia animal model: After the modeling period, the serum triglycerides, total cholesterol or low-density lipoprotein cholesterol in the hyperlipidemia model group increased compared with the blank control group, and the difference was significant, indicating that the model was established.
[0036] 3. Experimental methods
[0037] 3.1 Animal grouping
[0038] First random grouping: After the animals were received, they were fed adaptively for 5-7 days. During the acclimation period, the appearance and general condition of the animals were observed. Only animals that passed the inspection could enter this experiment. After the adaptation period, the animals were weighed and randomly divided into a blank control group (ND) and a high-fat model group.
[0039] Second random grouping: After the animal hyperlipidemia model was established, the animal blood lipids were tested and the hyperlipidemia model group was randomly divided into a hyperlipidemia model control group (HFD), a low-dose group of the test drug (25 ml / kg body weight) (HFD-GK-L), a medium-dose group of the test drug (50 mg / kg body weight) (HFD-GK-M), a high-dose group of the test drug (100 mg / kg body weight) (HFD-GK-H), and a positive control group (atorvastatin calcium group, 2 mg / kg body weight) (HFD-ATV).
[0040] 3.2 Hyperlipidemia model establishment period
[0041] As shown in Table 1, in each experimental group, the blank control group was fed with maintenance feed, and the remaining groups were fed with high-fat feed, and the levels of triglyceride, total cholesterol and low-density lipoprotein in the animal serum were measured.
[0042] The animals in the blank control group and the high-fat model group were fasted and blood was collected from the canthus. After blood collection, serum was separated and serum TC, TG and LDL-C levels were measured. The high-fat model group was randomly divided into groups according to TC, TG and LDL-C levels, and TC, TG and LDL-C were compared with those in the blank control group.
[0043] Table 1. Drug administration and diet of animals in each group
[0044] Group Dosing frequency Dosing cycle Dosage diet Number of golden hamsters Blank control group Oral gavage once a day 10 days 10ml / kg body weight normal 7 Hyperlipidemia model control group Oral gavage once a day 10 days 10ml / kg body weight High fat 7 Low dose group Oral gavage once a day 10 days 25 mg / kg body weight High fat 7 Medium dose group Oral gavage once a day 10 days 50mg / kg body weight High fat 7 High dose group Oral gavage once a day 10 days 100 mg / kg body weight High fat 7 Positive control group Oral gavage once a day 10 days 2mg / kg body weight High fat 7
[0045] 3.3 Dosing Period
[0046] The animals in the successfully grouped test drug (high, medium, and low dose) groups and the positive control group (atorvastatin calcium group) were given oral administration every day, and the blank control group and the hyperlipidemia model control group were given corresponding doses of solvent (blank control group: distilled water; hyperlipidemia model control group: olive oil). The dosage of each group is shown in Table 1.
[0047] The feeding conditions remained unchanged. Blood was collected from the canthus 10 days after administration to determine the levels of TC, TG and LDL-C in the animal serum and the levels of TC and TG in the liver tissue homogenate. The effects of the test drugs on TC, TG, LDL-C in the animal serum and TC and TG in the liver were observed, and the diameter of the animal liver was detected by ultrasound.
[0048] 3.4 Observation period
[0049] General vital signs were observed during the experiment.
[0050] 3.5 Main testing indicators
[0051] (1) Serum TC, TG and LDL-C levels.
[0052] (2) Ultrasonic detection of animal liver diameter.
[0053] (3) After sampling, the levels of TC and TG in liver tissue homogenate were measured.
[0054] 4. Experimental data and results
[0055] 4.1 Data processing
[0056] Variance analysis was used, but the variance homogeneity test must be performed first according to the procedure of variance analysis. If the variance is homogeneous, the F value is calculated. If the F value is <0.05, the conclusion is that there is no significant difference in the means of each group; F value ≥ 0.05, P ≤ 0.05, and the statistics are performed using the pairwise comparison method of the means between multiple experimental groups and a control group; for non-normal data or data with uneven variance, appropriate variable transformation is performed, and after meeting the requirements of normality or homogeneity of variance, the transformed data is used for statistics; if the normality or homogeneity of variance is still not achieved after the variable transformation, the rank sum test is used for statistics.
[0057] 4.2 Determination of Animal Experimental Results
[0058] Results of lipid lowering function: Compared with the blank control group, the hyperlipidemia model control group showed significant increases in serum triglycerides, total cholesterol and low-density lipoprotein, and the model was established.
[0059] Compared with the hyperlipidemia model control group, the serum total cholesterol, triglycerides and low-density lipoprotein in each dose group of the test drug decreased, and the differences were significant. It can be determined that the animal experiment results of the test drug's lipid-lowering function are positive.
[0060] Compared with the hyperlipidemia model control group, the cholesterol and triglyceride levels in the liver tissue homogenate of each dose group of the test drug were reduced, and the differences were significant. At the same time, the cholesterol and triglyceride levels in each dose group of the test drug were not significantly higher than those in the hyperlipidemia model control group. It can be determined that the animal experiment results of the test drug's function of lowering cholesterol and triglycerides are positive.
[0061] Compared with the hyperlipidemia model control group, the liver diameter of any dose group of the test drug was reduced, and the difference was significant. At the same time, the liver diameter of each dose group of the test drug was not significantly higher than that of the hyperlipidemia model control group. It can be determined that the animal experiment results of the test drug's function of reducing triglycerides are positive.
[0062] 4.3 Experimental Results
[0063] The results are as follows Figure 1 As shown, after 10 days of administration, the serum total cholesterol ( ** P<0.01vs.ND), triglyceride ( **P<0.01vs.ND) and low-density lipoprotein ( ** P<0.01vs.ND) level was significantly increased, indicating that the model was successfully established.
[0064] Compared with the hyperlipidemia model control group, the low, medium and high doses of the tested drugs and atorvastatin calcium significantly reduced the serum TC( # P<0.05 vs. HFD, ## P<0.01vs.HFD), TG( ## P<0.01vs.HFD) and LDL-C( ## P<0.01vs.HFD).
[0065] Compared with the blank control group, the total cholesterol in the liver of the hyperlipidemia model group was ** P<0.01vs.ND) and triglycerides ( ** P<0.01vs.ND) level was significantly increased, indicating that the model was successfully established.
[0066] Compared with the hyperlipidemia model control group, the low, medium and high doses of the tested drugs could reduce the TC( ## P<0.01vs.HFD) and TG( # P<0.05 vs. HFD, ## P<0.01vs.HFD).
[0067] Compared with the blank control group, the hyperlipidemia model group golden hamsters ** P<0.01vs.ND), the liver diameter increased significantly, indicating that the model was successfully established.
[0068] Compared with the hyperlipidemia model control group, the low, medium and high doses of the tested drugs and atorvastatin calcium reduced the liver diameter of hyperlipidemia golden hamsters ( ## P<0.01vs.HFD).
[0069] Example 2: Efficacy test of Gankang on C57BL / 6 mouse animal model
[0070] 1. Experimental Materials
[0071] Experimental animals: 28 animals of uniform weight (healthy male C57BL / 6 mice (22±1 g)).
[0072] Test drug: 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester (Gankang)
[0073] Maintenance feed: purchased from Keao Xieli (Tianjin) Feed Co., Ltd.
[0074] High-fat feed: purchased from Beijing Huafukang Biotechnology Co., Ltd., the feed formula contains 20.0% sucrose, 15% lard, 1.2% cholesterol, 0.2% sodium cholate, appropriate amount of casein, calcium hydrogen phosphate, stone powder, etc. In addition to crude fat, the moisture, crude protein, crude fat, crude fiber, crude ash, calcium, and phosphorus of the high-fat feed must meet the national standards for maintaining feed. The feed is clean grade, vacuum packed, and stored at 4°C. The above percentages (%) are all weight percentages.
[0075] 2. Experimental Principle
[0076] Feeding animals with the above-mentioned high-fat feed containing cholesterol, sucrose, lard, and sodium cholate can form an animal model of lipid metabolism disorder. Then, administering drugs to the animals can detect the effects of the test drugs on hyperlipidemia, and determine the effects of the test drugs on the animals' lipid absorption, lipoprotein formation, and lipid degradation or excretion.
[0077] Determination of hyperlipidemia animal model: After the modeling period, the serum triglycerides, total cholesterol or low-density lipoprotein cholesterol in the hyperlipidemia model group increased compared with the blank control group, and the difference was significant, indicating that the model was established.
[0078] 3. Experimental methods
[0079] 3.1 Animal grouping
[0080] First random grouping: After the animals were received, they were fed adaptively for 5-7 days. During the acclimation period, the appearance and general condition of the animals were observed. Only animals that passed the inspection could enter this experiment. After the adaptation period, the animals were weighed and randomly divided into a blank control group (ND) and a high-fat model group.
[0081] Second random grouping: After the animal hyperlipidemia model was established, the animal blood lipids were tested and the hyperlipidemia model group was randomly divided into a hyperlipidemia model control group (HFD), a test drug group (HFD-GK), and a positive control group (atorvastatin calcium group) (HFD-ATV).
[0082] 3.2 Hyperlipidemia model establishment period
[0083] As shown in Table 2, in each experimental group, the blank control group was fed with maintenance feed, and the remaining groups were fed with high-fat feed, and the levels of triglyceride, total cholesterol and low-density lipoprotein in the animal serum were measured.
[0084] The animals in the blank control group and the high-fat model group were fasted and blood was collected from the canthus. After blood collection, serum was separated and serum TC, TG and LDL-C levels were measured. The high-fat model group was randomly divided into groups according to TC, TG and LDL-C levels, and TC, TG and LDL-C were compared with those in the blank control group.
[0085] Table 2. Drug administration and diet of animals in each group
[0086] Group Dosing frequency Dosing cycle dose diet Number of C57BL / 6 mice Blank control group Oral gavage once a day 8 weeks 10ml / kg body weight normal 7 Hyperlipidemia model control group Oral gavage once a day 8 weeks 10ml / kg body weight High fat 7 Test drug group Oral gavage once a day 8 weeks 100 mg / kg body weight High fat 7 Positive control group Oral gavage once a day 8 weeks 20 mg / kg body weight High fat 7
[0087] 3.3 Dosing Period
[0088] The animals in the successfully grouped test drug group and the positive control group (atorvastatin calcium group) were intragastrically administered with the drug every day, and the blank control group and the hyperlipidemia model control group were given corresponding doses of solvent (blank control group: distilled water; hyperlipidemia model control group: olive oil). The dosage of each group is shown in Table 2.
[0089] The feeding conditions remained unchanged. After 8 weeks of administration, blood was collected from the canthus to determine the levels of TC, TG and LDL-C in the animal serum and the levels of TC and TG in the liver tissue homogenate. The effects of the test drugs on TC, TG, LDL-C in the animal serum and TC and TG in the liver were observed, and the diameter of the animal liver was detected by ultrasound.
[0090] 3.4 Observation period
[0091] General vital signs were observed during the experiment.
[0092] 3.5 Main testing indicators
[0093] (1) Serum TC, TG and LDL-C levels.
[0094] (2) Ultrasonic detection of animal liver diameter.
[0095] (3) After sampling, the levels of TC and TG in liver tissue homogenate were measured.
[0096] 4. Experimental data and results
[0097] 4.1 Data processing
[0098] Variance analysis was used, but the variance homogeneity test must be performed first according to the procedure of variance analysis. If the variance is homogeneous, the F value is calculated. If the F value is <0.05, the conclusion is that there is no significant difference in the means of each group; F value ≥ 0.05, P ≤ 0.05, and the statistics are performed using the pairwise comparison method of the means between multiple experimental groups and a control group; for non-normal data or data with uneven variance, appropriate variable transformation is performed, and after meeting the requirements of normality or homogeneity of variance, the transformed data is used for statistics; if the normality or homogeneity of variance is still not achieved after the variable transformation, the rank sum test is used for statistics.
[0099] 4.2 Determination of Animal Experimental Results
[0100] Results of lipid lowering function: Compared with the blank control group, the hyperlipidemia model control group showed significant increases in serum triglycerides, total cholesterol and low-density lipoprotein, and the model was established.
[0101] Compared with the hyperlipidemia model control group, the test drug group had a significant decrease in serum total cholesterol, triglycerides and low-density lipoprotein, which indicated that the test drug had a positive animal experiment result in lowering blood lipids.
[0102] Compared with the hyperlipidemia model control group, the cholesterol and triglyceride levels in the liver tissue homogenate of the test drug group were reduced, and the differences were significant. At the same time, the cholesterol and triglyceride levels in each dose group were not significantly higher than those in the hyperlipidemia model control group. It can be determined that the animal experiment results of the test drug's cholesterol and triglyceride lowering function are positive.
[0103] Compared with the hyperlipidemia model control group, the liver diameter of the test drug group was reduced, and the difference was significant. At the same time, the liver diameter of the test drug group was not significantly higher than that of the hyperlipidemia model control group. It can be determined that the animal experiment results of the test drug's function in reducing triglycerides are positive.
[0104] 4.3 Experimental Results
[0105] The results are as follows Figure 2 Shown are the effects of Gankang on the levels of blood lipids TC (A), TG (B) and LDL-C (C), the levels of TC (D) and TG (E) in the liver, and the liver diameter (F, G) in C57BL / 6 mice with hyperlipidemia, where G is an ultrasound image of the liver.
[0106] As can be seen from the figure, after 8 weeks of administration, the levels of total cholesterol (**P<0.01vs.ND), triglyceride (*P<0.05vs.ND) and low-density lipoprotein (**P<0.01vs.ND) in the serum of the hyperlipidemia model control group C57BL / 6 mice were significantly increased compared with those of the blank control group C57BL / 6 mice, indicating that the model was successfully established.
[0107] Compared with the hyperlipidemia model control group, the test drug group and atorvastatin calcium (positive control group) significantly reduced TC in the serum of hyperlipidemia C57BL / 6 mice ( ## P<0.01vs.HFD),TG( ## P<0.01vs.HFD) and LDL-C( # P<0.05vs.HFD).
[0108] The levels of total cholesterol (**P<0.01vs.ND) and triglyceride (*P<0.05vs.ND) in the liver of C57BL / 6 mice in the hyperlipidemia model control group were significantly increased compared with those in the blank control group, indicating that the model was successfully established.
[0109] Compared with the hyperlipidemia model control group, the test drug group could reduce the TC( # P<0.05vs.HFD) and TG( ## P<0.01vs.HFD).
[0110] The liver diameter of C57BL / 6 mice in the hyperlipidemia model control group was significantly increased compared with that of C57BL / 6 mice in the blank control group (**P<0.01vs.ND), indicating that the model was successfully established.
[0111] Compared with the hyperlipidemia model control group, the test drug group and atorvastatin calcium (positive control group) can reduce the liver diameter of hyperlipidemia C57BL / 6 mice ( ## P<0.01vs.HFD).
[0112] Example 3: Experimental study on the efficacy of Gankang on HepG2 cell line
[0113] 1. Experimental Materials
[0114] Experimental cells: HepG2 cell line
[0115] Test drug: 2-acetoxybenzoic acid 1,2-dihydroxyethyl ester (Gankang)
[0116] 2. Experimental Principle
[0117] The test drug is administered to cultured HepG2 cells for half an hour, and then oleic acid is added to induce a cell high-lipid model, so as to detect the effect of the test drug on the cellular lipid level.
[0118] 3. Experimental methods
[0119] 3.1 Cell grouping
[0120] When the cell confluence reached about 80%, 800 μmol / L of oleic acid was added to all groups except the normal group, and then divided into five groups: normal group (Ctrl), oleic acid-induced high-fat group (OA), low-dose GK group (OA+GK 2.5 μmol / L), medium-dose GK group (OA+GK 5 μmol / L) and high-dose GK group (OA+GK 10 μmol / L). After 24 hours, the levels of cellular cholesterol (TC) and triglyceride (TG) were detected.
[0121] 3.2 Detection methods
[0122] 3.2.1 Cell collection: scrape the cells with PBS to prepare cell suspension, centrifuge at 3000 rpm for 10 min, discard the supernatant and keep the cell pellet, wash 1-2 times with PBS, centrifuge at 3000 rpm for 10 min, discard the supernatant and keep the cell pellet.
[0123] 3.2.2 Cell disruption: Add 30 μL of PBS and disrupt by ultrasound.
[0124] 3.2.3 Determination method: First, the protein concentration of the sample was determined using the Bio-Tech kit. Then, 250 μL of working solution was added to the 96-well plate, 2.5 μL of distilled water was added to the blank well, 2.5 μL of calibration solution was added to the calibration well, and 2.5 μL of sample was added to the sample well. The plates were incubated at 37°C for 10 minutes, and the OD value was measured at 510 nm using an ELISA reader.
[0125] 3.2.4 Calculation formula:
[0126] Cholesterol content = (sample OD value - blank OD value) / (calibration OD value - blank OD value) * 5.17 / protein concentration of the sample to be tested
[0127] Triglyceride content = (sample OD value - blank OD value) / (calibration OD value - blank OD value) * 2.26 / protein concentration of the sample to be tested
[0128] 4. Experimental data and results
[0129] 4.1 Data processing
[0130] Variance analysis was used, but the variance homogeneity test must be performed first according to the procedure of variance analysis. If the variance is homogeneous, the F value is calculated. If the F value is <0.05, the conclusion is that there is no significant difference in the means of each group; F value ≥ 0.05, P ≤ 0.05, and the statistics are performed using the pairwise comparison method of the means between multiple experimental groups and a control group; for non-normal data or data with uneven variance, appropriate variable transformation is performed, and after meeting the requirements of normality or homogeneity of variance, the transformed data is used for statistics; if the normality or homogeneity of variance is still not achieved after the variable transformation, the rank sum test is used for statistics.
[0131] 4.2 Experimental Results
[0132] The results are as follows Figure 3 The figure shows the effect of Gankang on the levels of TC (A) and TG (B) in HepG2 cells induced by oleic acid and high fat. Compared with the blank control group (Ctrl), the total cholesterol ( ** P<0.01vs.Ctrl) and triglyceride ( **P<0.01vs.Ctrl) level was significantly increased, indicating that the model was successfully established. Compared with the cells in the oleic acid-induced high-fat group, the low, medium and high dose groups of Gankang could significantly reduce the TC ( ## P<0.01vs.OA) and TG( ## P<0.01vs.OA). This indicates that Gankang has the effect of lowering blood lipids, especially reducing total cholesterol, triglycerides and low-density lipoprotein in the serum of hyperlipidemic animals, and reducing the levels of total cholesterol and triglycerides in the liver and the diameter of the liver.
[0133] Example 4: Efficacy test of Gankang on liver fibrosis C57BL / 6 mouse model
[0134] 1. Experimental Materials
[0135] Experimental animals: 60 C57BL / 6 mice of uniform weight.
[0136] Test drug: 1,2-dihydroxyethyl 2-acetoxybenzoate (Gankang).
[0137] 2. Experimental Principle
[0138] A mouse model of liver fibrosis can be formed by intraperitoneal injection of carbon tetrachloride (CCl4) for 8 weeks. The effects of the test drugs on liver fibrosis can be detected by oral administration of drugs to mice for 4 weeks.
[0139] 3. Experimental methods
[0140] 3.1 Animal grouping
[0141] Random grouping: After the animals were received, they were adaptively fed for 3 days. After the adaptation period, the C57BL / 6 mice were randomly weighed and divided into 5 groups, namely, control group (Ctrl), liver fibrosis model group (CCl4), low-dose GK-L group (CCl4+GK-L), medium-dose GK-M group (CCl4+GK-M), and high-dose GK-H group (CCl4+GK-H).
[0142] 3.2 Establishment of liver fibrosis model
[0143] Mouse liver fibrosis model was established by intraperitoneal injection of carbon tetrachloride. Healthy male C57BL / 6 mice (22±1 g) were intraperitoneally injected with carbon tetrachloride (2 mg / kg) twice a week for 8 weeks. Figure 4 This is a schematic diagram of the animal experiment process of Gankang's anti-liver fibrosis.
[0144] 3.3 Medication and modeling period:
[0145] The SPF-level C57BL / 6 mice after adaptive feeding were randomly weighed and divided into 5 groups, namely the control group (Ctrl), liver fibrosis model group (CCl4), liver Kang low-dose group (CCl4+GK-L), liver Kang medium-dose group (CCl4+GK-M), and liver Kang high-dose group (CCl4+GK-H). From the fifth week of carbon tetrachloride induction, liver Kang and olive oil were given by gavage. After 4 consecutive weeks, the samples were taken for the detection of liver injury indicators. The dosage of liver Kang low-dose group was 25mg / kg, the dosage of liver Kang medium-dose group was 50mg / kg, and the dosage of liver Kang high-dose group was 100mg / kg. The dosage of distilled water in the control group was 10ml / kg body weight; the dosage of olive oil in the hyperlipidemia model control group was 10ml / kg body weight.
[0146] 3.4 Observation period
[0147] General vital signs were observed during the experiment.
[0148] 3.5 Main testing indicators
[0149] (1) After sampling, observe whether the mouse liver has granularity and lesions.
[0150] (2) After sampling, the liver weight to body weight ratio, serum and liver ALT and AST levels were measured.
[0151] (3) Determination of α-SMA protein.
[0152] 4. Experimental data and results
[0153] 4.1 Data processing
[0154] Variance analysis was used, but the variance homogeneity test must be performed first according to the procedure of variance analysis. If the variance is homogeneous, the F value is calculated. If the F value is <0.05, the conclusion is that there is no significant difference in the means of each group; F value ≥ 0.05, P ≤ 0.05, and the statistics are performed using the pairwise comparison method of the means between multiple experimental groups and a control group; for non-normal data or data with uneven variance, appropriate variable transformation is performed, and after meeting the requirements of normality or homogeneity of variance, the transformed data is used for statistics; if the purpose of normality or homogeneity of variance is still not achieved after variable transformation, the rank sum test is used for statistics instead.
[0155] 4.2 Experimental Results
[0156] The results are as follows Figure 5 The figure shows the effect of Gankang on the liver morphology of mice with liver fibrosis (the top shows the liver morphology at the beginning of the behavioral experiment, and the bottom shows the liver morphology at the end of the behavioral experiment). As can be seen from the figure, after sampling, the liver granularity of the model group was serious, and the liver granularity of the Gankang drug-administered groups (including low, medium and high dose groups) was significantly reduced.
[0157] like Figure 6 The figure shows the effect of Gankang on the liver weight to body weight ratio of mice with liver fibrosis. As can be seen from the figure, the liver weight to body weight ratio of the liver fibrosis model group increased significantly compared with the control group; compared with the liver fibrosis model group, the liver weight to body weight ratio of the Gankang administration group (including low dose, medium dose and high dose) decreased significantly, and the degree of decrease was proportional to the dose.
[0158] like Figure 7 The figure shows the effect of Gankang on the liver injury markers ALT (A) and AST (B) in the serum of mice with liver fibrosis. As can be seen from the figure, compared with the control group, the serum ALT and AST in the liver fibrosis model group increased significantly; compared with the liver fibrosis model group, the ALT and AST levels in the Gankang administration group (including low dose, medium dose and high dose) were significantly reduced.
[0159] like Figure 8 The figure shows the effect of Gankang on liver injury markers ALT (A) and AST (B) in liver tissue of mice with liver fibrosis. As can be seen from the figure, compared with the control group, the liver fibrosis model group had significantly increased ALT and AST in the liver tissue homogenate; compared with the liver fibrosis model group, the ALT and AST levels in the Gankang group were significantly reduced.
[0160] like Fig. 9 The figure shows the effect of Gankang on the expression of α-SMA protein in mice with liver fibrosis. The upper small figure is the Western blot result for determining the expression of α-SMA protein, and the lower part is the bar graph of α-SMA protein expression level. As can be seen from the figure, compared with the control group, the expression of α-SMA protein in the liver of the liver fibrosis model group increased significantly; compared with the liver fibrosis model group, the expression level of α-SMA protein in the liver of the Gankang administration group (including low dose, medium dose and high dose) was significantly reduced.
[0161] The above experimental results show that Gankang has anti-liver fibrosis effect, especially weakening liver fibrosis, reducing liver weight to body weight ratio, ALT and AST levels in serum and liver tissue homogenate.
Claims
1. Application of 1,2-dihydroxyethyl 2-acetoxybenzoate in the preparation of liver protection drugs, wherein the chemical structure of 1,2-dihydroxyethyl 2-acetoxybenzoate is as follows: .
2. The use according to claim 1, characterized in that: The liver protection drug is a lipid-lowering drug.
3. The use according to claim 2, characterized in that: The lipid-lowering drug reduces total cholesterol, triglyceride and low-density lipoprotein in the serum of hyperlipidemia animals, and reduces the levels of total cholesterol and triglyceride in the liver and the diameter of the liver.
4. The use according to claim 1, characterized in that: The liver protection drug is an anti-liver fibrosis drug.
5. The use according to claim 4, characterized in that: The anti-liver fibrosis drug reduces liver fibrosis, reduces the liver-to-body weight ratio, and reduces the ALT and AST levels in serum and liver tissue homogenate.
6. The use according to any one of claims 1 to 5, characterized in that The liver protection drug is in the form of capsules, tablets, powders, granules, sustained-release preparations, injections or any other pharmaceutically acceptable preparations.
